Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 known ✓ | P03956 | 1/20 | 0.56 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.56 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | MMP9 | P14780 | 1/20 | 0.56 |
| ▸ | F2 | P00734 | 3/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.50 |
| ▸ | RAPGEF4 | Q8WZA2 | 6/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | FABP4 | P15090 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYTH2 | Q99418 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL5999943 | 0.97 | CA1 (0.58) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL10846507 | 0.97 | CA1 (0.58) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL7930818 | 0.97 | CA1 (0.58) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL23788 | 0.97 | CA1 (0.58) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL2549047 | 0.95 | CA1 (0.56) | CA1CA2MMP1MMP2MMP9 | |
| Hydrochloric Acid SCHEMBL943801 | 0.95 | CA1 (0.56) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL9243736 | 0.95 | CA1 (0.56) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL28656334 | 0.95 | CA1 (0.56) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL28505545 | 0.95 | CA1 (0.56) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL9165332 | 0.95 | CA1 (0.56) | CA1CA2MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171437-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | VERA THERAPEUTICS INC (US) | 2021-06-10 | — | — | US | claimed |
| EP-3655388-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | Trucode Gene Repair, Inc. (US) | 2020-05-27 | — | — | EP | claimed |
| US-20190055190-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | NEUBASE THERAPEUTICS, INC. | 2019-02-21 | — | — | US | claimed |
| WO-2019018422-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TRUCODE GENE REPAIR, INC. (US) | 2019-01-24 | — | — | WO | claimed |
| CN-113117523-B | Forward osmosis extraction material, preparation method thereof and forward osmosis water desalination system using forward osmosis extraction material | 财团法人工业技术研究院 | 2023-02-03 | — | — | CN | disclosed |
| US-11273410-B2 | Extracted material for forward osmosis, preparation method thereof, and forward-osmosis water desalination system using the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2022-03-15 | — | — | US | disclosed |
| CN-113117523-A | Forward osmosis extraction material, preparation method thereof and forward osmosis water desalination system using forward osmosis extraction material | 财团法人工业技术研究院 | 2021-07-16 | — | — | CN | disclosed |
| US-20210197123-A1 | EXTRACTED MATERIAL FOR FORWARD OSMOSIS, PREPARATION METHOD THEREOF, AND FORWARD-OSMOSIS WATER DESALINATION SYSTEM USING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2021-07-01 | — | — | US | disclosed |
| US-20210171437-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | VERA THERAPEUTICS INC (US) | 2021-06-10 | — | — | US | disclosed |
| EP-3655388-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | Trucode Gene Repair, Inc. (US) | 2020-05-27 | — | — | EP | disclosed |
| US-20190055190-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | NEUBASE THERAPEUTICS, INC. | 2019-02-21 | — | — | US | disclosed |
| WO-2019018422-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TRUCODE GENE REPAIR, INC. (US) | 2019-01-24 | — | — | WO | disclosed |
| US-4879381-A | ANTIBIOTICS | TOYOMA CHEMICAL COMPANY, LTD. (JP) | 1989-11-07 | — | — | US | disclosed |
| US-4736026-A | REATING A 2-AMINOTHIAZOL-4-YL-2(SYN)-ALKOXYIMINOACETAMIDE AND A 7-AMINO-3-HET-METHYL-3-CEPHEM-4-CARBOXYLATE USING BORON TRIFLUORIDE CATALYST AND SOLVENT | TOYAMA CHEMICAL CO., LTD. (JP) | 1988-04-05 | — | — | US | disclosed |
| US-4673738-A | Novel intermediates of cephalosporins and process for producing 7-(substituted or unsubstituted amino)-3-substituted methyl-Δ3 -cephem-4-carboxylic acids | HANDI-PAC INC. (US) | 1987-06-16 | — | — | US | disclosed |
| US-4656287-A | Aminothiazole intermediate for a cephalosporin | TOYOMA CHEMICAL CO., LTD. (JP) | 1987-04-07 | — | — | US | disclosed |
| US-4614819-A | REACTING A THIOL ESTER COMPOUND WITH 7-AMINOCEPHALOSPORIN IN PRESENCE OF BORON TRIFLUORIDE | TOYAMA CHEMICAL CO., LTD. (JP) | 1986-09-30 | — | — | US | disclosed |
| US-4489091-A | ESTERASE AND ANTIBODY INHIBITORS | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1984-12-18 | — | — | US | disclosed |
| US-4489072-A | BACTERICIDE, ANTIBIOTIC | TOYAMA CHEMICAL CO., LTD. (JP) | 1984-12-18 | — | — | US | disclosed |
| US-4411911-A | Method of treating hyperlipidemia and inflammation with sulfonate derivatives | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1983-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055190-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TARBP1, TIA1, SSB | MMP1 4275/4885MMP8 3024/4885MMP13 3554/4885 |
| US-11273410-B2 | Extracted material for forward osmosis, preparation method thereof, and forward-osmosis water desalination system using the same | AQP1, AQP3, AQP4 | MMP1 1059/4885MMP8 1203/4885MMP13 581/4885 |
| US-20210171437-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TARBP1, TIA1, SSB | MMP1 4275/4885MMP8 3024/4885MMP13 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.